The following contraindications are listed by the manufacturer: * Hypersensitivity:<unk>  is contraindicated in patients with a known hypersensitivity to<unk>  or any of the inactive ingredients. * Monoamine oxidase inhibitors (MAOIs): concomitant use in patients taking MAOIs is contraindicated. * Uncontrolled narrow-angle glaucoma: in clinical trials, Cymbalta use was associated with an increased risk of mydriasis (dilation of the pupil); therefore, its use should be avoided in patients with uncontrolled narrow-angle glaucoma, in which mydriasis can cause sudden worsening. * Central nervous system (CNS) acting drugs: given the primary CNS effects of<unk> , it should be used with caution when it is taken in combination with or substituted for other centrally acting drugs, including those with a similar mechanism of action. *<unk>  and thioridazine should not be co-administered. In addition, the FDA has reported on life-threatening drug interactions that may be possible when co-administered with triptans and other drugs acting on serotonin pathways leading to increased risk for serotonin syndrome.
Duloxetine
Atomoxetine
Dapoxetine
Fluoxetine
Edivoxetine
Vortioxetine
Guanfacine
Nabilone